Association between IgG responses against the nucleocapsid proteins of alphacoronaviruses and COVID-19 severity.
COVID-19
SARS-CoV-2
coronavirus
multiplex serology
nucleocapsid protein
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
03
2022
accepted:
16
08
2022
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
Understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial to contain the COVID-19 pandemic. Using a multiplex approach, serum IgG responses against the whole SARS-CoV-2 proteome and the nucleocapsid proteins of endemic human coronaviruses (HCoVs) were measured in SARS-CoV-2-infected donors and healthy controls. COVID-19 severity strongly correlated with IgG responses against the nucleocapsid (N) of SARS-CoV-2 and possibly with the number of viral antigens targeted. Furthermore, a strong correlation between COVID-19 severity and serum responses against N of endemic alpha- but not betacoronaviruses was detected. This correlation was neither caused by cross-reactivity of antibodies, nor by a general boosting effect of SARS-CoV-2 infection on pre-existing humoral immunity. These findings raise the prospect of a potential disease progression marker for COVID-19 severity that allows for early stratification of infected individuals.
Identifiants
pubmed: 36159804
doi: 10.3389/fimmu.2022.889836
pmc: PMC9490404
doi:
Substances chimiques
Antibodies, Viral
0
Antigens, Viral
0
Immunoglobulin G
0
Nucleocapsid Proteins
0
Proteome
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
889836Informations de copyright
Copyright © 2022 Nückel, Planatscher, Mohr, Deichl, Mijočević, Feuerherd, Wolff, Erber, Schneider, Quante, Winter, Ruland, Hapfelmeier, Hammerschmidt, Moosmann, Protzer, Behrends and Mautner.
Déclaration de conflit d'intérêts
Author UP is receiving grants from Hoehnle AG, SCG Cell Therapy and VirBio and personal fees from Abbott, Abbvie, Arbutus, Gilead, GSK, J&J, Roche, Sanofi, Sobi and Vaccitech. UP is co-founder and shareholder of SCG Cell Therapy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Commun. 2021 Jan 4;12(1):6
pubmed: 33397903
PLoS One. 2007 Jul 04;2(7):e583
pubmed: 17611619
J Med Virol. 2021 Jan;93(1):311-322
pubmed: 32633840
ACS Cent Sci. 2020 Dec 23;6(12):2238-2249
pubmed: 33372199
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
mSphere. 2021 Apr 28;6(2):
pubmed: 33910993
Lancet Reg Health Eur. 2021 Jul;6:100122
pubmed: 34027514
Cell. 2021 Apr 1;184(7):1858-1864.e10
pubmed: 33631096
Clin Infect Dis. 2021 Nov 2;73(9):e3066-e3073
pubmed: 33147319
mBio. 2020 Sep 25;11(5):
pubmed: 32978311
Clin Infect Dis. 2021 Apr 8;72(7):1291-1292
pubmed: 32445559
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Viruses. 2020 Jun 10;12(6):
pubmed: 32532138
J Clin Virol. 2021 Jun;139:104847
pubmed: 33965698
Front Med (Lausanne). 2021 May 07;8:615099
pubmed: 34026773
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell Rep. 2021 Dec 28;37(13):110169
pubmed: 34932974
Mayo Clin Proc. 2020 Aug;95(8):1701-1703
pubmed: 32753142
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Analyst. 2021 Jan 21;146(2):382-402
pubmed: 33410826
Nat Immunol. 2020 Oct;21(10):1293-1301
pubmed: 32807944
Malawi Med J. 2012 Sep;24(3):69-71
pubmed: 23638278
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Nat Commun. 2021 Aug 6;12(1):4740
pubmed: 34362897
Cell Rep. 2021 May 25;35(8):109164
pubmed: 33991511
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
Immunity. 2020 Sep 15;53(3):524-532.e4
pubmed: 32783920
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
EBioMedicine. 2021 Jun;68:103401
pubmed: 34051441
J Infect. 2015 Nov;71(5):599-602
pubmed: 26165609
mSphere. 2021 Mar 10;6(2):
pubmed: 33692194
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
Emerg Microbes Infect. 2020 Dec;9(1):1664-1670
pubmed: 32618497
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Front Immunol. 2020 Dec 18;11:610688
pubmed: 33391281
Nat Commun. 2020 Jul 14;11(1):3581
pubmed: 32665645
Life (Basel). 2021 Apr 01;11(4):
pubmed: 33915711
Clin Vaccine Immunol. 2010 Dec;17(12):1875-80
pubmed: 20943876
Clin Immunol. 2020 Jun;215:108427
pubmed: 32325252
Sci Rep. 2019 Feb 4;9(1):1390
pubmed: 30718599
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Diagnostics (Basel). 2021 Jan 06;11(1):
pubmed: 33418886
J Med Virol. 2021 May;93(5):3211-3218
pubmed: 33620098
J Lab Clin Med. 1988 Nov;112(5):634-40
pubmed: 3183495
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32245835
Sci Transl Med. 2020 Jun 3;12(546):
pubmed: 32493791
Euro Surveill. 2021 Apr;26(13):
pubmed: 33797390
PLoS One. 2020 Nov 17;15(11):e0241955
pubmed: 33201896